BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27297970)

  • 21. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.
    Kang TY; Rybicki LA; Bolwell BJ; Thakkar SG; Brown S; Dean R; Sekeres MA; Advani A; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
    Bone Marrow Transplant; 2007 Nov; 40(10):973-8. PubMed ID: 17873917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
    J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
    Le Gouill S; Thieblemont C; Oberic L; Moreau A; Bouabdallah K; Dartigeas C; Damaj G; Gastinne T; Ribrag V; Feugier P; Casasnovas O; Zerazhi H; Haioun C; Maisonneuve H; Houot R; Jardin F; Van Den Neste E; Tournilhac O; Le Dû K; Morschhauser F; Cartron G; Fornecker LM; Canioni D; Callanan M; Béné MC; Salles G; Tilly H; Lamy T; Gressin R; Hermine O;
    N Engl J Med; 2017 Sep; 377(13):1250-1260. PubMed ID: 28953447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Follicular lymphoma: first - line selection criteria of treatment].
    Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
    Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.
    Ladetto M; Tavarozzi R; Zanni M; Evangelista A; Ferrero S; Tucci A; Botto B; Bolis S; Volpetti S; Zilioli VR; Puccini B; Arcari A; Pavone V; Gaidano G; Corradini P; Tani M; Cavallo F; Milone G; Ghiggi C; Pinto A; Pastore D; Ferreri AJM; Latte G; Patti C; Re F; Benedetti F; Luminari S; Pennese E; Bossi E; Boccomini C; Anastasia A; Bottelli C; Ciccone G; Vitolo U
    Ann Oncol; 2024 Jan; 35(1):118-129. PubMed ID: 37922989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
    Andreadis C; Schuster SJ; Chong EA; Svoboda J; Luger SM; Porter DL; Tsai DE; Nasta SD; Elstrom RL; Goldstein SC; Downs LH; Mangan PA; Cunningham KA; Hummel KA; Gimotty PA; Siegel DL; Glatstein E; Stadtmauer EA
    Bone Marrow Transplant; 2005 Dec; 36(11):955-61. PubMed ID: 16205727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
    Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R
    Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
    Montoto S; Matthews J; Greaves P; Lillington D; Anderson D; Gribben JG; Lister TA
    Haematologica; 2013 Apr; 98(4):620-5. PubMed ID: 23144201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
    Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
    Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
    Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
    Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.
    Arcaini L; Morello L; Tucci A; Rusconi C; Ladetto M; Rattotti S; Bonfichi M; Bottelli C; Gabutti C; Bernasconi P; Varettoni M; Gotti M; Troletti D; Guerrera ML; Fiaccadori V; Sciarra R; Ferretti VV; Alessandrino EP; Rossi G; Morra E
    Am J Hematol; 2015 Mar; 90(3):230-4. PubMed ID: 25502635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
    Lenz G; Dreyling M; Schiegnitz E; Forstpointner R; Wandt H; Freund M; Hess G; Truemper L; Diehl V; Kropff M; Kneba M; Schmitz N; Metzner B; Pfirrmann M; Unterhalt M; Hiddemann W;
    Blood; 2004 Nov; 104(9):2667-74. PubMed ID: 15238420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.